Fatty fish and omega-3: the winning combination against migraines

In brief

• Dietary interventions that increase omega-3 fatty acids (EPA/DHA) and, in some studies, reduce linoleic acid (LA) have shown reductions in migraine hours and days in controlled trials.
• Proposed biological mechanisms involve oxidized lipid mediators (oxylipins), resolvins, and endocannabinoid signals that modulate nociception.
• The best evidence comes from controlled trials and biochemical studies; however, limitations remain regarding duration, studied populations, and generalizability.
• For the public: results suggest that the quality of dietary fats can influence pain, but any major dietary change requires discussion with a doctor or nutritionist.

Abstract: what does science say?

The topic is the relationship between two main classes of dietary fatty acids — long-chain omega-3s (EPA and DHA, typical of fatty fish) and linoleic acid (LA, abundant in many vegetable oils) — and the frequency/intensity of migraines. Experimental and clinical evidence indicates that increasing EPA/DHA, sometimes combined with reducing linoleic acid, modifies lipid mediator profiles (oxylipins, resolvins, endocannabinoids) associated with pain regulation and can reduce headache hours and migraine days in some studied populations. These effects are biologically plausible but do not equate to universal cure evidence: they depend on dose, duration, diet composition, migraine definition (episodic vs. chronic), and pharmacological co-interventions. Longer studies, replications in different contexts, and analyses that causally link biochemical variations to clinical outcomes are needed.

The Facts: Migraine and the Role of Dietary Fats

Migraine is a common neurological condition that can cause recurrent headache attacks, often associated with nausea, photophobia, and limitation of daily activities. In recent clinical studies on patients with frequent migraines, nutritional interventions have been compared to assess whether modifying dietary fats can influence the frequency and intensity of pain. Research focuses particularly on two fronts: increasing the intake of EPA and DHA (long-chain omega-3s) typically found in fatty fish, and reducing the intake of linoleic acid (LA), an omega-6 widely present in vegetable oils.

These two dietary modifications are not equivalent: omega-3 EPA/DHA are precursors of mediators with potential antinociceptive and pro-resolving properties, while some oxygenated derivatives of linoleic acid (oxylipins from LA) are implicated in pronociceptive processes in preclinical models. Together, alterations in the levels of these lipids can change the balance of circulating and tissue lipid mediators that modulate pain sensitivity and inflammatory response [3][8].

The controlled study: what was done and what it showed

A randomized, controlled trial in participants with frequent migraines compared three dietary regimens for 16 weeks: one that increased EPA+DHA (H3), one that increased EPA+DHA and simultaneously reduced linoleic acid (H3-L6), and a control with usual intake. Meals provided to participants included portions of fatty fish, vegetables, and foods calibrated to achieve macronutrient targets. The analysis evaluated headache days per month, headache hours per day, intensity, medication use, and impact on quality of life.

The main results showed that diets with higher omega-3 intake, especially when associated with a reduction in linoleic acid, reduced total daily headache hours and monthly headache days compared to the control, with clinically relevant reductions in some sub-analyses. The authors also reported measurable changes in circulating lipid mediators consistent with the observed clinical effects [1].

Plausible biological mechanisms

Biological plausibility is based on the enzymatic conversion of fatty acids into oxygenated mediators (oxylipins), resolvins, and other lipid products. EPA and DHA give rise to resolvins and maresins that promote the resolution of inflammation and can reduce nociceptive sensitization; some precursor molecules such as 17‑HDHA have been associated with higher pain thresholds in human studies [3].

On the other hand, linoleic acid (LA) can be converted into pro-nociceptive oxylipins that activate sensory channels (e.g., TRP) and receptors involved in pain transmission; preclinical experiments show that some LA metabolites promote hyperalgesia and neural sensitization [5][7].

Furthermore, dietary interventions that modify EPA/DHA and LA also alter endocannabinoid signals and other lipid autacoids related to pain control, a possible link between dietary change, biochemical variation, and clinical response [2]. However, human mechanistic evidence remains partial: many biochemical associations are consistent but do not alone demonstrate a direct causal link with pain reduction.

What this means in practice

For those living with migraine, evidence suggests that the fat composition in the diet can influence the frequency and duration of attacks in some people. This does not mean that a universal "nutritional cure" exists: the observed effects are mediated by many variables (dietary baseline, disease severity, concomitant pharmacological therapies, dietary adherence, intervention duration) and vary among individuals.

From a practical standpoint, some elements of caution and common sense: consider including food sources rich in EPA/DHA (e.g., oily fish, salmon, mackerel) as part of a balanced diet; be aware that many industrial vegetable oils are rich in linoleic acid; discuss with your doctor or a nutritionist before making drastic changes or starting high-dose supplements. In particular, very marked reductions in LA or high omega-3 supplementation should be evaluated on a case-by-case basis, taking into account medications, comorbidities, and individual preferences [1].

Key points to remember

• Controlled trials indicate that increasing dietary EPA/DHA can reduce migraine hours and days in some patients; the effect may be greater if linoleic acid is also reduced. [1]
• Probable mechanisms involve oxylipins, resolvins, and endocannabinoids that modulate nociception, but direct proof of causality remains incomplete. [2][3]
• Not everyone responds in the same way: individual variability, intervention duration, and adherence are important determinants.
• Dietary changes should be discussed with a doctor, especially if taking medications or having chronic conditions.
• Longer studies are needed, in diverse populations and with biochemical measures that directly link lipid mediators to clinical changes.

Limitations of the Evidence

Observational Studies vs. Causal Evidence

Observational studies exist that associate lipid profiles with pain intensity and sensitivity, but only randomized controlled trials (RCTs) can provide stronger evidence of a causal relationship. Even in RCTs, however, it is necessary to distinguish between association and mechanism: changes in circulating lipid profiles may accompany, but not necessarily explain, pain reduction [2][9].

Methodological Limitations

Some recurring limitations include the relatively short duration of studies (weeks to a few months), modest sample sizes, the difficulty of controlling dietary adherence and contamination, and variability in measured biochemical results. Quality of life measures and reliance on self-reported headache diaries can introduce measurement bias. As required by clinical science, independent replications and studies with prolonged endpoints are needed.

Context Variability and Generalizability

The populations studied often include volunteers with frequent migraines and specific demographic characteristics; therefore, the results may not be fully generalizable to all people with migraines, nor can they be automatically extended to other forms of chronic pain without adequate experimental evidence. Genetic factors, concomitant medications, and underlying dietary patterns can also modify the effect.

Editorial Conclusion

Clinical and experimental literature converges on a plausible picture: increasing EPA/DHA intake and, in some models, reducing linoleic acid can modify lipid mediators involved in pain regulation and result in a reduction in migraine hours and days for some patients. However, the transition from "evidence of efficacy in some studies" to "universal clinical recommendation" requires further confirmation: longer-duration studies, diverse populations, analyses of mediators demonstrating causal mediation, and long-term safety evaluations. Pending these confirmations, healthcare professionals can consider the quality of dietary fats as a potentially useful element in the multidimensional approach to migraine management, always integrated with pharmacological treatment and other non-pharmacological strategies as needed.

Editorial Note

This article is an informative update based on peer-reviewed research. The purpose is to explain evidence, limitations, and practical implications in a clear and balanced way: it does not constitute personalized therapeutic advice. For clinical decisions, consult your doctor or a nutritionist.

Scientific research

1. Ramsden CE, Zamora D, Faurot KR, et al. Dietary alteration of n‑3 and n‑6 fatty acids for headache reduction in adults with migraine: randomized controlled trial. BMJ. https://doi.org/10.1136/bmj.n1448. [cited in text as [1]]
2. Ramsden CE, Zamora D, Makriyannis A, et al. Diet‑induced changes in n‑3‑ and n‑6‑derived endocannabinoids and reductions in headache pain and psychological distress. J Pain. 2015; doi: 10.1016/j.jpain.2015.04.007. [cited in text as [2]]
3. Valdes AM, Ravipati S, Menni C, et al. Association of the resolvin precursor 17‑HDHA, but not D‑ or E‑ series resolvins, with heat pain sensitivity and osteoarthritis pain in humans. Sci Rep. 2017;7:10748. doi: 10.1038/s41598-017-09516-3. [cited in text as [3]]
4. Ramsden CE, Ringel A, Majchrzak‑Hong S, et al. Dietary linoleic acid‑induced alterations in pro‑ and anti‑nociceptive lipid autacoids: implications for idiopathic pain syndromes? Mol Pain. 2016; doi: 10.1177/1744806916636386. [cited in text as [4]]
5. Ruparel S, Hargreaves KM, Eskander M, et al. Oxidized linoleic acid metabolite‑cytochrome P450 system is active in human tissue from inflammatory dental pain. Pain. 2013; doi: 10.1016/j.pain.2013.07.011. [cited in text as [5]]
6. Djalali M, Talebi S, Djalali E, et al. The effect of omega‑3 fatty acids supplementation on inflammatory biomarkers in subjects with migraine: a randomized, double‑blind, placebo‑controlled trial. J Nutr Intermed Metab. 2023; doi: 10.1080/08923973.2023.2196600. [cited in text as [6]]
7. Wolfram et al. (Biochemical Pharmacology). Oxidized linoleic acid metabolites maintain mechanical and thermal hypersensitivity during sub‑chronic inflammatory pain. Biochem Pharmacol. 2022; doi: 10.1016/j.bcp.2022.114953. [cited in text as [7]]
8. Review: Oxylipins Derived from PUFAs in Cardiometabolic Diseases: Mechanism of Actions and Possible Nutritional Interactions. Nutrients. 2024;16:3812. doi: 10.3390/nu16223812. [cited in text as [8]]